118 related articles for article (PubMed ID: 38635931)
1. Prognostic Model for High-Grade Neuroendocrine Carcinoma of the Lung Incorporating Genomic Profiling and Poly (ADP-ribose) Polymerase-1 Expression.
Kim HS; Kim JK; Lee JH; Lee YJ; Lee GK; Han JY
JCO Precis Oncol; 2024 Apr; 8():e2300495. PubMed ID: 38635931
[TBL] [Abstract][Full Text] [Related]
2. Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
Shimada Y; Kudo Y; Maehara S; Matsubayashi J; Otaki Y; Kajiwara N; Ohira T; Minna JD; Ikeda N
Cancer Sci; 2020 Feb; 111(2):610-620. PubMed ID: 31845438
[TBL] [Abstract][Full Text] [Related]
3. Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer.
Kim HC; Song JS; Lee JC; Lee DH; Kim SW; Lee JS; Kim WS; Rho JK; Kim SY; Choi CM
Int J Clin Exp Pathol; 2014; 7(10):6743-51. PubMed ID: 25400754
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathological significance of cancer stem-like cell markers in high-grade neuroendocrine carcinoma of the lung.
Morise M; Hishida T; Takahashi A; Yoshida J; Ohe Y; Nagai K; Ishii G
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2121-30. PubMed ID: 25963795
[TBL] [Abstract][Full Text] [Related]
5. Percutaneous computed tomography-guided core needle biopsy can be used to histologically confirm the clinical features and long-term prognosis of pulmonary neuroendocrine neoplasms.
Chen C; Wang Y; Huang H; He X; Li W
Jpn J Radiol; 2023 Dec; 41(12):1414-1419. PubMed ID: 37395983
[TBL] [Abstract][Full Text] [Related]
6. Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.
Chang JG; Chen CC; Wu YY; Che TF; Huang YS; Yeh KT; Shieh GS; Yang PC
Oncotarget; 2016 Nov; 7(45):73664-73680. PubMed ID: 27655641
[TBL] [Abstract][Full Text] [Related]
7. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
8. Expression of ERCC1, MSH2 and PARP1 in non-small cell lung cancer and prognostic value in patients treated with platinum-based chemotherapy.
Xie KJ; He HE; Sun AJ; Liu XB; Sun LP; Dong XJ
Asian Pac J Cancer Prev; 2014; 15(6):2591-6. PubMed ID: 24761869
[TBL] [Abstract][Full Text] [Related]
9. Clinical significance of MYC family protein expression in surgically resected high-grade neuroendocrine carcinoma of the lung.
Oshima Y; Haruki T; Matsui S; Makishima K; Sakabe T; Umekita Y; Nakamura H
Thorac Cancer; 2023 Mar; 14(8):758-765. PubMed ID: 36694106
[TBL] [Abstract][Full Text] [Related]
10. Combined high-grade neuroendocrine carcinoma of the lung: clinicopathological and immunohistochemical study of 34 surgically resected cases.
Yamada K; Maeshima AM; Tsuta K; Tsuda H
Pathol Int; 2014 Jan; 64(1):28-33. PubMed ID: 24471967
[TBL] [Abstract][Full Text] [Related]
11. PARP1 expression and its correlation with survival is tumour molecular subtype dependent in glioblastoma.
Murnyák B; Kouhsari MC; Hershkovitch R; Kálmán B; Marko-Varga G; Klekner Á; Hortobágyi T
Oncotarget; 2017 Jul; 8(28):46348-46362. PubMed ID: 28654422
[TBL] [Abstract][Full Text] [Related]
12. Poly ADP-ribose polymerase-1 as a potential therapeutic target in Merkel cell carcinoma.
Ferrarotto R; Cardnell R; Su S; Diao L; Eterovic AK; Prieto V; Morrisson WH; Wang J; Kies MS; Glisson BS; Byers LA; Bell D
Head Neck; 2018 Aug; 40(8):1676-1684. PubMed ID: 29570891
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive Characterization of the Genomic Landscape in Chinese Pulmonary Neuroendocrine Tumors Reveals Prognostic and Therapeutic Markers (CSWOG-1901).
Peng W; Cao L; Chen L; Lin G; Zhu B; Hu X; Lin Y; Zhang S; Jiang M; Wang J; Li J; Li C; Shao L; Du H; Hou T; Chen Z; Xiang J; Pu X; Li J; Xu F; Loong H; Wu L
Oncologist; 2022 Mar; 27(2):e116-e125. PubMed ID: 35641209
[TBL] [Abstract][Full Text] [Related]
14. Negative prognostic value of high levels of intracellular poly(ADP-ribose) in non-small cell lung cancer.
Michels J; Adam J; Goubar A; Obrist F; Damotte D; Robin A; Alifano M; Vitale I; Olaussen KA; Girard P; Cremer I; Castedo M; Soria JC; Kroemer G
Ann Oncol; 2015 Dec; 26(12):2470-7. PubMed ID: 26387143
[TBL] [Abstract][Full Text] [Related]
15. High proportion of tumor necrosis predicts poor survival in surgically resected high-grade neuroendocrine carcinoma of the lung.
Sugimoto A; Umemura S; Miyoshi T; Nakai T; Kuroe T; Nosaki K; Ikeda T; Udagawa H; Kirita K; Zenke Y; Matsumoto S; Yoh K; Niho S; Tsuboi M; Goto K; Ishii G
Lung Cancer; 2021 Jul; 157():1-8. PubMed ID: 34049251
[TBL] [Abstract][Full Text] [Related]
16. DEK oncoprotein regulates transcriptional modifiers and sustains tumor initiation activity in high-grade neuroendocrine carcinoma of the lung.
Shibata T; Kokubu A; Miyamoto M; Hosoda F; Gotoh M; Tsuta K; Asamura H; Matsuno Y; Kondo T; Imoto I; Inazawa J; Hirohashi S
Oncogene; 2010 Aug; 29(33):4671-81. PubMed ID: 20543864
[TBL] [Abstract][Full Text] [Related]
17. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of perioperative chemotherapy for pulmonary high-grade neuroendocrine carcinomas: a propensity score matching analysis.
Ogawa H; Tanaka Y; Kitamura Y; Shimizu N; Doi T; Hokka D; Tane S; Nishio W; Yoshimura M; Maniwa Y
J Thorac Dis; 2019 Apr; 11(4):1145-1154. PubMed ID: 31179056
[TBL] [Abstract][Full Text] [Related]
19. PARP1 expression in soft tissue sarcomas is a poor-prognosis factor and a new potential therapeutic target.
Bertucci F; Finetti P; Monneur A; Perrot D; Chevreau C; Le Cesne A; Blay JY; Mir O; Birnbaum D
Mol Oncol; 2019 Jul; 13(7):1577-1588. PubMed ID: 31131495
[TBL] [Abstract][Full Text] [Related]
20. A pilot study of adjuvant chemotherapy with irinotecan and cisplatin for completely resected high-grade pulmonary neuroendocrine carcinoma (large cell neuroendocrine carcinoma and small cell lung cancer).
Kenmotsu H; Niho S; Ito T; Ishikawa Y; Noguchi M; Tada H; Sekine I; Watanabe S; Yoshimura M; Yamamoto N; Oshita F; Kubota K; Nagai K
Lung Cancer; 2014 Jun; 84(3):254-8. PubMed ID: 24679951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
